Public information shows that in recent times, the global biopharmaceutical, life science tools, and high-end medical equipment tracks have continued to heat up. A group of high-quality domestic enterprises that are deeply rooted in cutting-edge innovation fields and have core technological barriers have intensively disclosed the progress of a new round of financing.
The companies that have obtained financing cover a wide range of high prosperity sub sectors, including extracellular vesicle industrialization, primary cell and CGT raw materials, synthetic biology, sugar and nucleic acid drug raw materials, in vivo CAR-T/circular RNA, localization of orthodontic instruments, high-end neuroscience imaging instruments, and oral surgical robots. These enterprises actively explore cutting-edge directions such as the integration of AI and biotechnology, and the localization of high-end instruments, promoting the comprehensive upgrading of China’s biopharmaceutical industry chain from source innovation to industrial transformation.

1、 Huixin Biotechnology has completed an A+round of financing of nearly 100 million yuan, strengthening the barrier of extracellular vesicle separation and purification technology

On February 9th, Shenzhen Huixin Biomedical Technology Co., Ltd. (hereinafter referred to as “Huixin Biotechnology”) officially announced the completion of an A+round of nearly 100 million yuan financing, led exclusively by Junlian Capital. It is worth noting that in the past year, Huixin Biotechnology has completed two consecutive rounds of financing worth nearly 100 million yuan, fully reflecting the high recognition of the capital market for its original underlying technological strength, industrialization landing ability, and industry development potential.

The purpose of this round of financing funds is clear and focused on: the key investment will be in the field of multiple types of nanoparticles (including exosomes, viruses, LNP, etc.), accelerating the industrialization process of highly integrated fully automatic separation and purification technology platforms, promoting the leapfrog upgrade of related technologies from laboratory research and development processes to industrial level intelligent manufacturing systems, and effectively solving the core pain points of large-scale production in the industry.

As a life science enterprise driven by original underlying technology, Huixin Biotechnology has established a complete product matrix covering scientific research to industrial production. Its independently developed EXODUS series equipment, including scientific grade EXODUS H-300/H-600 and industrial grade EXODUS T-2800, is equipped with a disposable exosome enrichment and purification kit, which can fully cover the full scenario requirements from laboratory small-scale sample processing to GMP standard large-scale production, forming a differentiated technical barrier that is difficult to replicate.
In the future, Huixin Biotechnology will focus on deepening the deep integration of physical AI and nanoparticle separation and purification technology, and creating an integrated full process solution of “equipment+data+process”; The relevant person in charge of Junlian Capital stated that they highly value the original technological advantages, full chain industrial layout, and industry standard setting ability of Huixin Biotechnology, and believe that the enterprise has outstanding long-term industrial value and core competitiveness.

2、 Heyousheng Biotechnology has completed tens of millions of yuan in Pre-A round financing, accelerating domestic substitution and global layout in the field of primary cells

On February 9th, Wuxi Heyousheng Biotechnology Co., Ltd. (hereinafter referred to as “Heyousheng Biotechnology”) officially announced the completion of tens of millions of yuan in Pre-A round financing, which is exclusively invested by Guolian Jintou Zhiyuan. This financing is not only a recognition of the potential development of the primary cell track by the capital market, but also a high affirmation of the core technological strength, product competitiveness, and industrialization ability of Heyousheng Biotechnology. At the same time, it is also a key capital layout move for the company within a year, injecting strong momentum into its future development.

It is reported that the funds raised in this round of financing will be directed towards two core directions: firstly, to promote the iterative upgrading of the company’s GMP level products, continuously improve product quality and production capacity, and further consolidate the integrated solution of products and services with primary cells as the core; The second is to accelerate the global business layout, promote the international commercialization of core products and technical services, and strengthen the market influence of enterprises in the global primary cell field.

As an innovative biotechnology enterprise focusing on primary cells and related reagents and technical services, Heyousheng Biotechnology is deeply rooted in the fields of cell and gene therapy (CGT) and large molecule drugs. Relying on its independent research and development platform, it has built a complete service system of “sample service – characteristic products – technical service platform”, with core business covering primary immune cells, stem cells, liver cells and other fields. Its subsidiary HiXpan ® Featured products such as cell culture and HiMag sorting kits have successfully broken the long-term monopoly of foreign countries and achieved domestic innovation breakthroughs.After financing, Heyousheng Biotechnology will accelerate the improvement of its product matrix and deepen its core advantages in domestic substitution; Guolian Jintou Zhiyuan will continue to increase its support, helping enterprises achieve breakthroughs in technology research and development, production capacity construction, and market expansion, and promoting the high-quality development of China’s biopharmaceutical industry through independent innovation.

3、 Shenbi Biotechnology has completed tens of millions of yuan in Pre-A round financing, solidifying the technological barriers in synthetic biology

On February 6th, Shenbi Biotechnology officially announced the completion of tens of millions of yuan in Pre-A round financing, led exclusively by Bailian Zhigao. This financing not only highly recognizes the potential for the development of synthetic biology in the capital market, but also confirms the company’s core technological strength and commercial landing ability in the fields of synthetic biology and plant gene editing, injecting strong capital support for the company’s subsequent innovative development.

It is reported that the funds raised in this round will be focused on three major directions, focusing on the technological iteration of plant cell chassis synthesis biological platform, accelerating the industrialization and market expansion of core products, and helping the company to continue to break through in the fields of luminescent plants and the synthesis of bioactive substances. Established in March 2023, Shenbi Biotechnology focuses on innovative underlying technologies in synthetic biology and plant gene editing. The core team gathers top talents in the field and has built a full chain technology system from laboratory research and development to large-scale production.

The core advantage of the company lies in its independently developed plant cell chassis synthetic biology platform, which has established the “world’s first dual gene (TAL tyrosine pathway) pathway patent” system, significantly improving substrate conversion efficiency and luminescent enzyme half-life. It has successfully cultivated the first high brightness stable self luminous plant in China and expanded to more than 20 plant species. Bailian Zhigao expressed confidence in its technology conversion capability and platform strategic value. As a veteran shareholder, Meihua Venture Capital also recognizes its technological foresight and commercialization path, and will continue to empower the company’s growth in the future.

4、 Tangzhi Pharmaceutical has completed a strategic financing of over 100 million yuan, strengthening its core advantages in the fields of sugar and nucleic acid

On February 6th, Wuhan Tangzhi Pharmaceutical Co., Ltd. (hereinafter referred to as “Tangzhi Pharmaceutical”) officially completed a strategic financing of over 100 million yuan. This round of financing was jointly invested by AstraZeneca Zhongjin Medical Industry Fund, Huaxin Capital, Guangxin Fund, Guanggu Financial Holdings, and Shifengxin Hui, demonstrating the high recognition of the sugar and nucleic acid track and the core competitiveness of enterprises in the capital market, injecting strong impetus into the company’s global layout and technological innovation.

Founded in 2019, Tangzhi Pharmaceutical has built a complete industrial value chain covering research and development, production, and commercialization, relying on more than 30 years of chemical enzyme synthesis biology technology accumulation, core raw materials and technical solutions for caramel, nucleic acid, and their derivatives. With the integrated technology platform of chemistry, enzyme catalysis, and biosynthesis, the company has broken through the bottleneck of innovative drug raw material production capacity, overcome multiple “bottleneck” technologies, and achieved domestic substitution of key pharmaceutical raw material intermediates. Its products are widely used in downstream high growth fields such as ADC and oligonucleotide drugs, and have gained recognition from domestic and foreign top customers.

This round of financing exceeding 100 million yuan will be used to deepen global cooperation, enhance the industrialization capability of innovative products, and promote the application and landing of sugar and nucleic acid technology in the field of life sciences. All investors have expressed confidence in Tangzhi Pharmaceutical’s technological accumulation, engineering capabilities, and market potential. In the future, it will continue to empower the company, help it build a core competitiveness in global sugar drug raw materials, and empower China’s biopharmaceutical industry to innovate independently and develop with high quality.

5、 Lilly plans to acquire Orna for up to $2.4 billion, increasing its focus on in vivo CAR-T and circular RNA track layout

On February 9th local time, multinational pharmaceutical company Eli Lilly and circular RNA therapy company Orna Therapeutics reached a final acquisition agreement. Eli Lilly will acquire Orna in a cash transaction, and its shareholders are expected to receive up to $2.4 billion in consideration, covering down payments and follow-up payments related to clinical development milestones. This acquisition demonstrates Eli Lilly’s strategic determination to lay out in vivo CAR-T and circular RNA fields.

As a representative platform enterprise in the post mRNA era, Orna’s core technology focuses on engineered circular RNA and novel LNP delivery systems. It has been incubated based on relevant research from MIT and has built a complete in vivo CAR-T engineering platform. Its leading project ORN-252 (in vivo CAR-T therapy targeting CD19) is entering the clinical trial preparation stage, focusing on the treatment of B cell-driven autoimmune diseases, with outstanding preclinical data performance.

The core value of this acquisition lies in Orna’s technology integration capability, which can directly drive CAR expression in vivo by combining circular RNA vectors with immune biased LNP systems, solving the pain points of complex and costly traditional autologous CAR-T in vitro preparation. Lilly’s move aims to fill the gaps in the field of in vivo cell engineering and align with its innovative layout in the fields of immunology and genetic medicine. In the future, the market will focus on the clinical progress of the project and the effectiveness of technology platform integration.

6、 Ankeruqi completes angel round financing of millions, accelerating the localization process of orthodontic devices

On February 10th, Jiangsu Ankeruqi Medical Technology Co., Ltd. (hereinafter referred to as “Ankeruqi”) officially announced the completion of a multi million dollar angel round financing. The investors in this round include Kunshan Angel Fund and Xuedian Asset, with Weina Capital serving as the exclusive financial advisor and participating in the follow-up investment. This is the first time that the company has introduced a professional equity investment institution, and the funds raised will focus on the localization research and development of orthodontic devices, as well as the domestic education and promotion of orthodontic anchorage technology.

Ankeruqi has been deeply involved in the field of orthodontics for many years. Since its predecessor was founded in 2015, the company has built a full chain ecosystem covering medical device sales, medical education and training, dental clinic operations, and product research and production. It has established a mature sales and academic system by representing overseas leading orthodontic products, and has also laid out its own research sector. In collaboration with experts from universities, it has launched multiple orthodontic devices, built independent production lines, and obtained multiple NMPA registration certificates.

The investors in this investment all have deep industrial resources, among which Kunshan Angel Fund is the first national funded angel fund in a county in China, and Xuedian Asset focuses on the life and health track. The combination of the two will help Ankeruqi strengthen its self-developed strength, improve the industrial closed loop, further break through the dependence on imported oral orthodontic devices, accelerate the process of domestic substitution, and consolidate its full ecological competitive advantage in the industry.

7、 Chaoweijing has completed a B+round financing of over 100 million yuan, opening a new chapter in its “high-end scientific instruments+brain computer” strategy

On February 10th, Beijing Chaoweijing Biotechnology Co., Ltd. (hereinafter referred to as “Chaoweijing”) officially announced the completion of a B+round financing of over 100 million yuan. This round is jointly invested by five institutions with deep industrial backgrounds, including Guangdong Traditional Chinese Medicine Health Fund and Beijing Medical and Health Industry Investment Fund. It coincides with the company’s 10th anniversary, and this financing marks a critical stage for its technological industrialization and ecological layout.

Founded by Academician Cheng Heping of the Chinese Academy of Sciences, Chaoweijing has been deeply involved in the field of high-end biomedical imaging since its establishment in 2016. Its core advantage lies in the comprehensive breakthrough of miniaturized multiphoton imaging technology, which has achieved complete autonomy and controllability of key core components, breaking foreign monopolies. Its world’s first multi-color miniaturized two-photon microscope and other products can achieve high-resolution imaging of deep brains in freely moving animals.

This round of financing will be used for the research and development of new generation products, global layout, and the introduction of top talents. The company will deepen its “high-end scientific instruments+brain computer” dual wheel drive strategy, promote the transformation of technology into clinical practice, and expand its global market. At present, its products have been exported to top global institutions such as Harvard and Oxford. With the joint support of multiple institutions, it will further strengthen its technological barriers and help China’s high-end scientific research instruments to be independently controllable.

8、 Yangshan Medical has completed tens of millions of yuan in Pre-A round financing to help commercialize China’s first unobstructed surgical robot

Recently, Shanghai Yangshan Medical Technology Co., Ltd. (hereinafter referred to as “Yangshan Medical”) officially completed tens of millions of yuan in Pre-A round financing. This round is jointly led by Shanlan Capital and Yuanyi Capital, and the original shareholder Lanchi Venture Capital continues to increase its follow-up investment, demonstrating the high recognition of the capital market for the oral surgery robot track and the core competitiveness of the enterprise, injecting strong momentum into the commercialization of its core products.

Yangshan Medical focuses on providing full process solutions for oral and maxillofacial surgery. Its core advantage lies in its independent research and development capabilities. Its first unobstructed surgical robot in China is about to be applied in the field of oral implantation, with core features such as zero registration, unobstructed operation, and anti-interference. Combined with AI technology, it can assist doctors in efficiently and accurately completing surgeries; Another world’s first dental implant traction device has entered the special review process for innovative medical devices by the National Bureau and has won the second prize of National Science and Technology Progress Award.

This round of financing will focus on supporting the commercialization of China’s first unobstructed surgical robot, while also supporting the iteration of core technology and the improvement of product matrix.
All investors have expressed confidence in the technological barriers, scenario adaptation capabilities, and clear commercialization path of Yangshan Medical. In the future, they will rely on their own resources to empower the enterprise, help it accelerate market penetration, and promote the digitization and precision upgrading of the dental industry.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.